Precision medicine

Triple-negative breast cancer is not a single entity, and understanding each patient’s molecular subtype can influence treatment and outcomes

The move to in-house next-generation sequencing has resulted in time and tissue savings, and improved collaboration across cancer care specialties

Neurological disorders can be invasive and time-consuming to diagnose, but profiling cytokines in the cerebrospinal fluid can lessen that burden

From a new material for lung cancer diagnosis to real-time robotics for monitoring reproductive hormones, discover our latest bite-sized breakthroughs

Jane Armes discusses the value of molecular subtyping and targeted therapies in triple-negative breast cancer

Liquid biopsy has shown promise as a rapid, minimally invasive way to profile tumors – but are commercially available tests accurate and consistent?

Variants in the FUT2 gene may increase susceptibility to otitis media by altering the microbiome of the middle ear

The use of saliva as a diagnostic fluid seems an attractive option – especially now that research reveals circulating tumor DNA in the fluid

The FLEX breast cancer registry intends to collect complete information on 10,000 patients over the course of 10 years

Newly discovered genetic alterations could indicate whether treatment or active surveillance is the best option for low-risk prostate cancer patients